Alzheimer Disease Clinical Trial
Official title:
Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Interest on Video Recognition and Actigraphy
Cognitive and memory disorders are characterized of Alzheimer disease. In addition,
psychologic and behavioural symptoms, called speak neuropsychiatric symptoms, are frequents
and play an important role in prognostic and intervention. These symptoms are noticed before
the diagnostic of dementia, their prevalence and their intensity increase with the evolution
of disease. Apathy, which is characterized by a decrease of motivation, is the most frequent
of this behaviour disrupt. Clinically, a decrease, or a totally, lack of interest,
initiative and blunting emotional are noticed. Fundamentally, apathy is considered as a
decrease of cognition and behaviour to "go in goal". Assessment of psychological and
behavioural symptoms is realised principally with neuropsychiatric scales. These contribute
to obtain particular informations about health of patient allowing by patient and caregiver
discussions and impressions of clinician. These scales are simples but loss of subjectivity.
An alternative of this method is the use of gerontechnology as actigraphy (system
out-patient which records locomotive activity with the help of piezo-electrical sensor fixed
on a bracelet) and video recording which is associated to an informatic treatment of signal
in order event recognition.
The aim of study is to realise an objective assessment of activities "go in goal" during
experimental sequence which has well-characterized acts, using at the same time an
actigraphic record of activity "motive" (system of assessment indirect of apathy fit) and a
video records which uses an informatic event recognition system. The assessment will realise
with participants controls (n=30) and Alzheimer disease patients with (n=20) or without
(n=20) apathy, during well-characterized records. The final aim is to obtain a particular
assessment of some disorders behaviours, as apathy, which is principally characterize by a
decrease of behaviours "to go in goal".
| Status | Completed |
| Enrollment | 82 |
| Est. completion date | June 2012 |
| Est. primary completion date | December 2011 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 65 Years and older |
| Eligibility |
Inclusion Criteria for no mnesic patient: - man or female, more 65 years ; - no caregiver ; - no motor handicap ; - no global cognitive impairment with > 26 MMSE, neither argument in favour of following diagnosis : Alzheimer's disease, major depressive episode ; - no apathy ; - participant with french national health ; - signature of informed consent. Inclusion Criteria for Alzheimer's patient: - man or female, more 65 years ; - no motor handicap ; - with diagnosis of Alzheimer's disease according to criteria of NINCDS-ADRDA ; - apathy score > 3 in Neuropsychiatric Inventory ; - with a MMSE score lower than 26/30 ; - with cholinesterase inhibitor medication, standard and stable dose since 3 month ; - no global cognitive impairment with > 26 MMSE, neither argument in favour of following diagnosis : Alzheimer's disease, major depressive episode ; - no apathy ; - participant with french national health ; - signature of informed consent. Exclusion Criteria: - Impossibility of realization of the experimental protocol because of a driving handicap. - Port(Bearing) of a pacemaker - Under guardianship Patient or guardianship |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Country | Name | City | State |
|---|---|---|---|
| France | Hôpital de Cimiez | Nice |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Universitaire de Nice |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | stride and speed walking | one time point - at the only visit of protocol (day 1) | No | |
| Secondary | For comparison between Alzheimer disease patients with (n=20) or without apathy, we use again stride and speed walking | one time point - at the only visit of protocol (day 1) | No | |
| Secondary | For reproducibility, we use stride and speed walking | one time point - at the only visit of protocol (day 1) | No | |
| Secondary | Reliability is the sum of posture's concordance | one time point - at the only visit of protocol (day 1) | No | |
| Secondary | Relation between LF/HF variations and activity index | one time point - at the only visit of protocol (day 1) | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
| Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
| Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
| Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
| Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
| Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
| Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
| Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
| Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
| Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
| Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
| Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
| Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
| Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
| Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
| Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
| Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
| Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
| Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |